Sign in

    Vishwesh Shah

    Biotechnology Equity Research Associate at TD Cowen

    Vishwesh Shah is a Biotechnology Equity Research Associate at TD Securities (TD Cowen), specializing in the biotechnology sector with a focus on companies developing treatments in sleep medicine and neurological disorders. He has contributed research on market drivers such as the narcolepsy and idiopathic hypersomnia markets, evaluating key therapeutic pipelines and catalysts, including those for companies pursuing orexin 2 receptor agonists. Shah joined TD Cowen in early 2024, building on a career in life sciences equity research; his professional licenses include FINRA registration (CRD# 7766024). He is recognized for deep sector diligence, incorporating key opinion leader feedback and market analytics in his research coverage.

    Vishwesh Shah's questions to Aurinia Pharmaceuticals (AUPH) leadership

    Vishwesh Shah's questions to Aurinia Pharmaceuticals (AUPH) leadership • Q2 2025

    Question

    Vishwesh Shah of TD Cowen inquired about the strategic potential of Aratinircept, asking where Aurinia sees the most value and what doses might be advanced based on recent study data. He also asked about the impact of updated ACR guidelines on Lupkynis adoption and the current prescribing trends between rheumatologists and nephrologists.

    Answer

    President and CEO Peter Greenleaf explained that while Aratinircept has potential in over 20 B-cell mediated diseases, specific indications are not being disclosed for competitive reasons. Chief Medical Officer Dr. Greg Keenan added that Phase 1 data supports a Q4-week dosing schedule. Regarding Lupkynis, Mr. Greenleaf confirmed the ACR guidelines have driven a notable increase in prescribing from rheumatologists and growth in the hospital segment.

    Ask Fintool Equity Research AI

    Vishwesh Shah's questions to Aurinia Pharmaceuticals (AUPH) leadership • Q2 2025

    Question

    Vishwesh Shah inquired about the potential indications for Aratinacept, the dosing strategy following the Phase 1 SAD study, and the impact of updated ACR guidelines on LUPKYNIS adoption among rheumatologists and nephrologists.

    Answer

    President and CEO Peter Greenleaf highlighted that Aratinacept could target over 20 B-cell mediated diseases but declined to specify indications for competitive reasons. Chief Medical Officer Dr. Greg Keenan confirmed that SAD study data supports a Q4-week dosing schedule. Peter Greenleaf also noted that the ACR guidelines have driven a strong uptick in prescribing from rheumatologists and growth in the hospital setting.

    Ask Fintool Equity Research AI

    Vishwesh Shah's questions to Aurinia Pharmaceuticals (AUPH) leadership • Q2 2025

    Question

    Vishwesh Shah inquired about the strategic thinking behind Aratinacept's development, potential high-value indications, and dosing plans based on recent PK/PD data. He also asked about the impact of updated ACR guidelines on LUPKYNIS prescribing trends between rheumatologists and nephrologists.

    Answer

    CEO Peter Greenleaf noted a wide range of over 20 potential B-cell mediated diseases for Aratinacept but declined to specify targets for competitive reasons. CMO Dr. Greg Keenan confirmed that Phase 1 data supports a Q4-week dosing schedule for future studies. Regarding LUPKYNIS, Greenleaf highlighted a strong uptick in rheumatology prescribers and hospital business as direct positive impacts of the new guidelines.

    Ask Fintool Equity Research AI

    Vishwesh Shah's questions to Aurinia Pharmaceuticals (AUPH) leadership • Q2 2025

    Question

    Vishwesh Shah inquired about the strategic development and potential value of Aratinacept (AUR-200), including dosing for future studies, and asked for an update on LUPKYNIS adoption trends following the updated ACR guidance, specifically regarding rheumatology versus nephrology prescribing.

    Answer

    President and CEO Peter Greenleaf highlighted that Aratinacept could target over 20 B-cell mediated diseases but declined to specify indications for competitive reasons. Chief Medical Officer Dr. Greg Keenan confirmed that data supports a Q4 week dosing schedule for future studies. Regarding LUPKYNIS, Greenleaf noted a significant increase in prescribing from rheumatologists and growth in the hospital segment, which he attributed in part to the new guidelines.

    Ask Fintool Equity Research AI